Scarica l'app Stockscreener
467.01
0.28%
1.31
Dopo l'orario di chiusura:
467.01
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$465.70
Aprire:
$465.19
Volume 24 ore:
1.07M
Relative Volume:
1.04
Capitalizzazione di mercato:
$119.87B
Reddito:
$10.63B
Utile/perdita netta:
$-479.80M
Rapporto P/E:
35.03
EPS:
13.33
Flusso di cassa netto:
$-1.35B
1 W Prestazione:
-6.92%
1M Prestazione:
-3.31%
6M Prestazione:
+4.90%
1 anno Prestazione:
+33.24%
Intervallo 1D:
$458.05
$468.88
Intervallo di 1 settimana:
$458.05
$508.04
Portata 52W:
$346.29
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Confronta VRTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Braun Stacey Associates Inc. - MarketBeat
3 Growth Stocks You Can Buy Right Now Without Any Hesitation - The Motley Fool
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Swiss National Bank - MarketBeat
Atlanta Consulting Group Advisors LLC Purchases 1,331 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Empowered Funds LLC Sells 17,482 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Natixis Advisors LLC - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Position Lifted by Mizuho Securities USA LLC - MarketBeat
Kentucky Retirement Systems Trims Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
CIBC Asset Management Inc Acquires 4,432 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Impax Asset Management Group plc Has $3.46 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Broderick Brian C Increases Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Huntington National Bank - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Rating Upgraded by Citigroup - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stake Increased by KBC Group NV - MarketBeat
Citigroup Initiates Coverage of Vertex Pharmaceuticals (VRTX) with Buy Recommendation - MSN
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Gilead, Vertex initiated as new big biotech buys at Citi - Seeking Alpha
Vertex Pharmaceuticals Shows Rising Relative Strength; Still Shy Of Key Benchmark - MSN
Sivik Global Healthcare LLC Trims Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Aubrey Capital Management Ltd Takes Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Earns Buy Rating from Analysts at Citigroup - MarketBeat
Pinnacle Financial Partners Inc Grows Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex’s upcoming sciatica trial readout is a high-stakes moment in its quest to quell pain - STAT
Vertex Pharmaceuticals' SWOT analysis: cystic fibrosis leader faces pipeline tests - Investing.com
Insider Sale at Vertex Pharmaceuticals Inc (VRTX) by EVP & CFO C - GuruFocus.com
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Chase Investment Counsel Corp Has $3.28 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Victory Capital Management Inc. Lowers Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Aptus Capital Advisors LLC Buys 3,071 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Baillie Gifford & Co. Lowers Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
WealthPlan Investment Management LLC Takes $635,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity - sharewise
Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Rating Upgraded by StockNews.com - MarketBeat
Vertex Pharmaceuticals CEO sells $7.83 million in stock - Investing.com
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Cumberland Partners Ltd - MarketBeat
Hemenway Trust Co LLC Has $18.66 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Sumitomo Mitsui Trust Group Inc. Boosts Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Los Angeles Capital Management LLC Decreases Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Mayflower Financial Advisors LLC - MarketBeat
Atria Investments Inc Sells 1,564 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
SpiderRock Advisors LLC Grows Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Fiera Capital Corp Has $2.86 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
6,307 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Purchased by CWA Asset Management Group LLC - MarketBeat
Lindbrook Capital LLC Raises Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Assetmark Inc. Has $94.91 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Galvin Gaustad & Stein LLC Decreases Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Rising Revenue & Strategic Pipeline Advances Propel Biotech Growth Trajectory - Streetwise Reports
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.69%
1.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):